drugset / Trial / NCT06866964
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Phase 2
Recruiting
35 enrolled
Wake Forest University Health Sciences
Atrium Health Wake Forest Baptist · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Timeline
- Start
- 2025-08-28
- Primary completion
- 2029-08
- Completion
- 2031-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | Oral |